Asterand Bioscience Strategic Alliances

Similar documents
Business Development Manager Technical Specialist

CAP Accreditation Checklists 2016 Edition

Precision Biospecimen Solutions: Paving the Way to Personalized Medicine

TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT

Molecular Diagnostics

CAP Accreditation Checklists 2017 Edition

Specialty Lab Services. Deep science at scale

IBBL: Introduction to Biobanks and their services

Central Laboratory Services. Anatomic Pathology Histology Services

University of New Mexico Health Sciences Center Office of Research Policy for the Oversight of Human Tissue in Research

The Lifecycle of a Sample

The SWOG Biospecimen Bank: investing in the future of translational research

Leveraging an Academic-Industry Partnership for Commercial Success

Le banche dei tessuti

Billing Contact: Phone: Type of Research: NIH Funded Industry Funded Department Funded Study Name: CTRC Protocol: Start Date: End Date:

Controlled Document Number: Version Number: 2 Controlled Document Sponsor: Controlled Document Lead:

Diagnostic Laboratory New Facility Registration Pre-Assessment Data Verification Form

Data Mining for Genomic- Phenomic Correlations

Tissue Tug of War: Issues in tissue procurement for research and banking

Session: Innovative Technologies

Using Human Tissue in Translational Research and Clinical Trials

Developing Common Biorepository Infrastructures

2010 NORTH AMERICAN TISSUE DIAGNOSTICS PRODUCT LINE STRATEGY AWARD

Explore the World of End-to-End. Integrated Lab Performance

Konica Minolta to Acquire Invicro (US)

Centre for NanoHealth

THE WHITE HOUSE Office of the Vice President

Title: Department: Approved by: Director, Human Research Review and Compliance. KEYWORDS: IRB, Institutional Review Board

227 AP and >100 CDx engagements

WHITE PAPER FACTORS TO CONSIDER WHEN OUTSOURCING BIOREPOSITORY SERVICES

Preanalytical Variables in Blood Collection: Impact on Precision Medicine

Making More Efficient Use of Biospecimens. ISBER Contributions and Initiatives

REIMAGINING DRUG DEVELOPMENT:

Feature. Who Owns Diagnostic Tissue Blocks? Sarah Dry, MD (David Geffen School of Medicine, Los Angeles, CA)

Feature. Who Owns Diagnostic Tissue Blocks? Sarah Dry, MD (David Geffen School of Medicine, Los Angeles, CA) DOI: /LM3XP8HBKDSGICJH

Optimising Clinical Laboratory Operations. Alan Brown SLAS Compound Management March 2017

DIAGNOSE AND TREAT WITH ANTIBODIES THAT RECOGNIZE NATIVE HUMAN PROTEIN EPITOPES IN BLOOD AND TISSUE

Alliance for Regenerative Medicine

Stanford University IRB Guidance On Data and Tissue Repositories

Nanthealth Patient Informed Consent

Hepatic ADME-Tox Products & Research Services

Integrated Radiology & Pathology Diagnostic Services: The Time is Now at UCLA

Patient Handbook on Stem Cell Therapies

Your bridge to. better medicines

UE Biopathologie et Biobanking

American Society of Cytopathology Core Curriculum in Molecular Biology

Course Agenda. Day One

Ensuring Translational Scientific Understanding Underpins Your Biomarker-Dx Strategy. Thomas Krahn Bayer Pharma AG

Technology Development Funding Program Round 3

Knight Cancer Institute Cancer Early Detection Advanced Research Center (CEDAR) Call for Clinical Matched Case Control Sample Collection

LYSARC, ACADEMIC PARTNER OF LYMPHOMA CLINICAL RESEARCH. EN

What does Big Pharma want?

Ethics of Precision Medicine in Low to Middle Income Countries

LYSARC, ACADEMIC PARTNER OF LYMPHOMA CLINICAL RESEARCH. EN

TOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS

Vision, aims and strategies. Department of Immunology, Genetics and Pathology Uppsala University

STUDY INFORMATION Principal Investigator: Phone: Primary Coordinator: Phone:

TRANSLATIONAL RESEARCH IN RARE AND NEUROMUSCULAR DISEASES - WHY DATA SHARING MATTERS. H a n n s Lochmüller, Newcastle University

The King s Liver Research Tissue Bank

UNLEASH THE POWER OF PRECISION MEDICINE

Customer Manual. General instructions for molecular diagnostic tests

Career Growth Areas in Physiology / Pharmacology

Cancer Research UK; $500m annual research spend on basic research, drug discovery and clinical development

Higher National Diploma Biomedical Science

Advancing Life Sciences

Megan Schmidt Vice President of Product Management, CompuGroup Medical

1.0 Background to the organisation

Biotech / Life Science Sector

leading the way in research & development

October Nasdaq (CGIX) A Leader in Precision Oncology. Nasdaq (CGIX)

IBBL BIOSERVICES SAMPLE ANALYSIS & QUALITY CONTROL

What is biomedical science?

RESEARCH OFFICER CANCER PATHOLOGY

Molecular Diagnosis Challenges & Solutions. Using Molecular Kits or Laboratory Developed Tests (Home Brew), Emphasis on Validation

Participant Information

Preanalytical Processing: The Biospecimen Quality Imperative

Advancing utility and adoption of clinical genomic diagnostics

NHS ENGLAND BOARD PAPER

the PLATFORM Pipeline in Lyon AREA

Belgium, a European leader in clinical trials

Innovative Medicines Initiative (IMI) Future funding opportunities. Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017

TheraLin. Universal Tissue Fixative Enabling Molecular Pathology

Topic: Genome-Environment Interactions in Inflammatory Skin Disease

Working Together for Better Health Partnering with Boehringer Ingelheim. JOURNEE COLLABORATIVE DE LYONBIOPOLE October 10, 2017

2018 North American Real-World Evidence Enterprise Solutions Market Leadership Award

A Report on the Molly and David Bloom Chair in Multiple Myeloma Research at the Princess Margaret Cancer Centre

Lead the way. Molecular Imaging. GE Healthcare. imagination at work

BIOSCIENTIA. Good outcomes are based on good values. Central lab services and biomarker analytics for clinical trials

BIOHEALTH INDUSTRY. Start Your Career in Wisconsin s BIOTECH AND BIOPHARMA MEDICAL DEVICE AND DIAGNOSTICS HEALTH RESEARCH INSTITUTES BIO- MANUFACTURE

VERMONT. Bioscience Performance Metrics. Vermont Page 1

CONNECTICUT. Bioscience Performance Metrics. Connecticut Page 1

Interview. Maximizing the Value of Biospecimens to Deliver New Therapies. with Clive Green, PhD, Director and Head of Sample Management at AstraZeneca

Companion diagnostics and the IVD Directive 98/79/EC + revision

Introduction of Development Center for Biotechnology TAIWAN

LAB EXPERTS AT YOUR SIDE Over twenty years of experience

ROUND TABLE ARISLA Milano 26 marzo 2014 Le BioBanche Nodo Italiano di Biobanking and Biomolecular Resources Research Infrastructure

The patient must address the treating physician directly if he/she has any questions or requires information regarding the test results.

Accelerating the Adoption of Companion Diagnostics

Transcription:

Asterand Bioscience Strategic Alliances Excellence through partnership www.asterandbio.com

WHY ASTERAND BIOSCIENCE Asterand Bioscience has a well-established human tissue heritage, having been formed in 2006 through the merger of Asterand (founded 2000), a human tissue biorepository, and Pharmagene (founded 1996), a human tissue-based drug discovery company. With our capability in human tissue sample procurement, characterization and service, Asterand Bioscience is uniquely positioned to provide a comprehensive approach to meet the research needs of pharmaceutical, biotechnology and diagnostic companies, and academia. From our offices in Detroit, MI and Royston, U.K., our employees are focused on providing services and products to accelerate drug discovery research from target identification through to compound evaluation and preclinical drug and diagnosis development. ESTABLISHED AND PROSPECTIVE SOLUTIONS Asterand Bioscience offers unparalleled access to human biosamples through its worldwide network of active collaborating donor institutions. Our XpressBANK contains specimens across a broad range of therapeutic areas and with diverse ethnic representation. Our renowned quality control procedures provide stringent oversight on specimen collection and characterization and on the corresponding associated clinical data. We independently confirm pathology with our in-house board certified pathologists and assess RNA integrity of our tissues. Our quality control results are provided to researchers before they purchase so they can choose samples that will best meet their scientific requirements. Through our ProCURE service, human tissues and clinical data can also be custom collected to meet special requirements. This may include the collection of follow-up data related to patient treatment and outcome. DRUG DISCOVERY SERVICES Asterand Bioscience s services division offers exemplary scientific expertise in human tissue research, with experience in providing top multinational pharmaceutical companies with human tissuebased services since 1996. Through our PhaseZERO drug discovery services platform, we provide a collaborative scientific approach to deliver human tissue-based data on target & biomarker validation as well as compound potency, effect and safety. Our studies can be custom designed and are conducted on a fee-for-service basis where our clients own and retain all resulting IP and data.

WHO WE ARE? Asterand Bioscience is the leading global provider of high quality, well characterized human tissue and biofluid samples and human tissue-based research solutions to drug discovery scientists. Our mission is to provide human-based solutions to accelerate the identification and validation of drug targets and enhance the selection of drug candidates with an increased likelihood of clinical success. Asterand Bio Human Tissue Products (XpressBANK, BioSPOKE ) and Services (PhaseZERO ) Phase 1 Phase 2 Phase 3 Approval 5,000-10,000 Compounds Target Identification Biomarker Discovery Target Validation Lead Identification Lead Optimization ADME Preclinical Clinical 1 Approved Drug Preclinical discovery and development 3-6 years Clinical development 7-9 years STRATEGIC ALLIANCE PARTNERS Asterand Bioscience, in conjunction with our Strategic Alliance Partners, is the leading provider of high quality human biosamples and associated clinical information. Our Strategic Alliance Partners follow rigorous criteria for the procurement and quality control of samples. Biosamples are acquired through different procurement means to best meet the research requirements of our customers through an IRB approved process.

WHY BECOME A STRATEGIC ALLIANCE PARTNER WITH ASTERAND BIOSCIENCE? Asterand Bioscience s research partners are the leading scientists in drug discovery for a wide range of diseases, including cancer, heart disease, autoimmune disorders, CNS diseases and more. Their progress is dependent on donated human diseased and normal tissues and biofluids that are used to accelerate and move their research from the bench to the clinic. Our tissue samples are consented for use in research and are excess to diagnostic and therapeutic needs and are not suitable for transplant. This provides individuals and families the option to participate in the advancement of drug discovery, contributing to the understanding of these diseases and to the development of new treatments, cures and diagnoses. THE ASTERAND BIOSCIENCE PROCESS Asterand Bioscience, a CAP accredited organization, has the experience and dedication to provide researchers the best quality specimens required for their research needs. Many facilities, including hospitals, tissue banks and organ procurement organizations, work with Asterand Bioscience to ensure the best outcomes for tissues donated from individuals and families wishing to help advance the understanding of disease and the development of new drugs and diagnostics. You can help further research, which will benefit the lives of millions.

Asterand Bioscience has a highly trained staff of scientists and technicians, who work with partner organizations to facilitate the best use of donated biospecimens. Asterand Bioscience has provided over 200,000 human biospecimens to an extensive group of long standing partners located world wide. CURRENT RESEARCH NEEDS Organs and tissues routinely discarded during standard treatment processes are critical for researchers working to understand biological mechanisms and drug discovery. Surgical discards Tumor, adjacent normal tissue and matched blood Explanted organs from transplant recipients and non-transplanted organs from organ donors Skin, fat and cartilage removed during surgery Autopsy tissues Normal and diseased tissues with short post-mortem recovery times Archived specimens Paraffin blocks, slides, and other archived specimens

ETHICAL LEADERSHIP AND REGULATORY CONTROL All human tissue samples are obtained with informed donor consent and are de-identified prior to banking and distribution. Asterand Bio acts in strict compliance with the US Health Insurance Portability and Accountability Act (HIPAA) and the United Kingdom Human Tissue Authority (HTA) and is accredited by the College of American Please contact our Strategic Alliance Directors in the following regions to discuss your requirements: United States Tech One, Suite 501 440 Burroughs Detroit, MI 48202 USA T: 313-263-0960 F: 313-263-0961 International 2A Orchard Rd. Royston, Hertfordshire, SG8 5HD UK T: +44 (0) 1763 211600 F: +44 (0) 1763 211555 Pathologists (CAP) and ISO 9001. DRUG DISCOVERY SERVICES: Immunohistochemistry In situ Hybridization Tissue MicroArrays Digital Pathology Fluorescent In situ Hybridization Histopathology Western Blotting Laser Capture Microdissection qrt-pcr Autoradiography Primary Cell Isolation and Culture Cell Based Assays Cell Based Assay Development OrganDOT sirna Target Knockdown Mutation Analysis THERAPEUTIC AREAS: Oncology Cardiovascular Disease Metabolic Disorders CNS Disorders Respiratory Diseases Inflammatory & Allergy Genitourinary System Diseases Normal Tissues BIOMATERIALS AVAILABLE: Flash-Frozen Tissues Fixed & Embedded Tissues Serum, Plasma, Blood Synovial Fluid RNA & DNA biomaterials Tissue MicroArrays Primary Cells and Cell Lines Unless otherwise noted, all trademarks are the property of Asterand Bioscience, Inc. 2015 Asterand Bioscience, Inc. All rights reserved. Issue Code: AB-SA-Partnership-0615 www.asterandbio.com